Rybelsus
semaglutide (oral) · Novo Nordisk
Form
Oral tablet
Frequency
Once daily (morning, on empty stomach)
Available Doses
FDA Approval Date
September 20, 2019
Mechanism
GLP-1 receptor agonist (peptide, oral formulation)
Manufacturer
Novo Nordisk
Cost
Self-Pay
~$936/mo
Covered by insurance for T2D. Not typically covered for weight loss (not FDA-approved for that indication).
Side Effects
| Side Effect | Rate | Source |
|---|---|---|
| Nausea | ~16-20% | PIONEER trials (dose-dependent) |
| Diarrhea | ~5-10% | PIONEER trials |
| Vomiting | ~5-8% | PIONEER trials |
| Constipation | ~3-5% | PIONEER trials |
| Abdominal pain | ~5-7% | PIONEER trials |
Source: PIONEER Clinical Trial Program (PIONEER 1-10)
Weight Loss Results
PIONEER trials
~4-5%
26-52 weeks · Multiple analyses
At 14mg dose in T2D patients. Limited weight loss due to lower dose and diabetes-focused patient population.
How It Works
Rybelsus works the same way as injectable semaglutide (Ozempic) once absorbed. The SNAC co-formulation protects semaglutide from stomach acid and enhances absorption. However, oral bioavailability is only ~1%, meaning the 14mg tablet delivers roughly the equivalent of a very low injectable dose.
Mechanism: Rybelsus was the first oral GLP-1 medication (approved 2019). Like oral Wegovy, it uses the SNAC absorption enhancer to enable oral delivery of semaglutide. Its maximum dose (14mg) is much lower than oral Wegovy's (25mg), limiting its weight loss efficacy. Rybelsus is approved for diabetes only.
Who It's For
Indication
Type 2 diabetes mellitus (not approved for weight loss)
Adults with type 2 diabetes who prefer an oral medication over injections. Not recommended for weight loss — oral Wegovy (higher doses) or Foundayo offer much better weight loss results. Rybelsus's main advantage is existing insurance coverage for diabetes.
Food & Water Restrictions
⚠️ Restrictions Apply
Must take on an empty stomach with ≤4oz plain water. Wait 30 minutes before eating, drinking, or taking other medications.
Switching Guides
Comparisons
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical trial data referenced comes from published studies and FDA prescribing information. Side effect rates are from specific clinical trials and may not reflect real-world experience. Always consult your healthcare provider before starting, stopping, or switching any medication.